Targepeutics is a biopharmaceutical company developing selective molecularly targeted therapeutics to fight cancer and other diseases. Our lead compound, GB-13, is currently nearing Phase I clinical trials for high-grade giloma (brain cancer), and is showing promise against other solid tumors. GB-13 is a genetically engineered recombinant protein that specifically binds and destroys cancer cells with minimal normal cell damage.